-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, March 25 NewsOn March 23, West China Hospital of Sichuan University released the latest new drug announcement.
A total of 41 new drugs were selected, including 22 imported (joint venture) drugs and 19 domestic drugs.
From the perspective of imported products, Novartis’s cucuzumab injection, Amgen’s disulumab injection and other star drugs are all listed.
In terms of domestic drugs, Hengrui has the largest number of three, namely carrelizumab for injection, paclitaxel for injection (albumin-bound type), and poppy lipiodol injection; Hausen, BeiGene, and Zhengdatian Qing has two drugs each selected.
It is worth mentioning that two PD-1 products were introduced this time, from Hengrui and BeiGene.
A total of 41 new drugs were selected, including 22 imported (joint venture) drugs and 19 domestic drugs.
From the perspective of imported products, Novartis’s cucuzumab injection, Amgen’s disulumab injection and other star drugs are all listed.
In terms of domestic drugs, Hengrui has the largest number of three, namely carrelizumab for injection, paclitaxel for injection (albumin-bound type), and poppy lipiodol injection; Hausen, BeiGene, and Zhengdatian Qing has two drugs each selected.
It is worth mentioning that two PD-1 products were introduced this time, from Hengrui and BeiGene.
Anti-tumor drugs are the "main force" entering the hospital
Starting from March 1 this year, the 2020 National Medical Insurance Catalogue will be implemented.
The new medical insurance catalog drugs are one of the necessary conditions for the introduction of West China Hospital into the hospital.
The new medical insurance catalog drugs are one of the necessary conditions for the introduction of West China Hospital into the hospital.
According to the new drug declaration principles issued by West China Hospital in January this year, the following conditions must be met at the same time: (1) Belonging to the "Sichuan Pharmaceutical Equipment pharmnet.
com.
cn/news/yyzb/" target="_blank">Procurement Supervision" platform for online products; (2) Complying with the National Medical Insurance Bureau and the Ministry of Human Resources and Social Security Basic medical insurance, work-related injury insurance and maternity insurance drug catalog (2020)"; (3) In accordance with the "National Basic Medical Insurance, Work-Injury Insurance and Maternity Insurance Drug Catalog (2020)", it must belong to "blood and hematopoietic drugs , the cardiovascular system, urogenital system drugs and sex hormones, sex hormones and insulin in addition to systemic hormone preparations, other anti -tumor drugs and immunomodulators "; (4) reporting the same enterprise limit SKUs two packets, if excess declaration, All declarations are considered "invalid".
com.
cn/news/yyzb/" target="_blank">Procurement Supervision" platform for online products; (2) Complying with the National Medical Insurance Bureau and the Ministry of Human Resources and Social Security Basic medical insurance, work-related injury insurance and maternity insurance drug catalog (2020)"; (3) In accordance with the "National Basic Medical Insurance, Work-Injury Insurance and Maternity Insurance Drug Catalog (2020)", it must belong to "blood and hematopoietic drugs , the cardiovascular system, urogenital system drugs and sex hormones, sex hormones and insulin in addition to systemic hormone preparations, other anti -tumor drugs and immunomodulators "; (4) reporting the same enterprise limit SKUs two packets, if excess declaration, All declarations are considered "invalid".
Judging from the types and quantities of drugs introduced this time, anti-tumor drugs and immunomodulators are still the main force, which also shows that hospitals have more urgent needs for new anti-tumor drugs.
At the same time, the proportion of domestic new drugs has further increased, including: Hengrui’s Carrelizumab for Injection, Paclitaxel for Injection (albumin-bound), and Ethidium Poppy Injection; and Hausen Pharmaceutical’s Ametylate Mesylate Tablets, flumatinib mesylate; Zebutinib capsules and tislelizumab injection from BeiGene; rivaroxaban tablets and fulvestrant injection from Zhengda Tianqing.
At the same time, the proportion of domestic new drugs has further increased, including: Hengrui’s Carrelizumab for Injection, Paclitaxel for Injection (albumin-bound), and Ethidium Poppy Injection; and Hausen Pharmaceutical’s Ametylate Mesylate Tablets, flumatinib mesylate; Zebutinib capsules and tislelizumab injection from BeiGene; rivaroxaban tablets and fulvestrant injection from Zhengda Tianqing.
For PD-1 drugs that have received much attention, the products of Hengrui and BeiGene have been included.
If the publicity is passed, plus the Cinda Sintilimab injection that was introduced in March 2020, a total of 3 PD-1 models will be admitted to West China Hospital.
If the publicity is passed, plus the Cinda Sintilimab injection that was introduced in March 2020, a total of 3 PD-1 models will be admitted to West China Hospital.
Since 4 domestically produced PD-1s have been significantly reduced in price and entered into medical insurance, the competition on the PD-1 track will become even more fierce.
On March 20th and 21st, Junshi and Cinda successively announced the launch of new indications for their PD-1 products nationwide.
For domestically produced PD-1, in addition to increasing indications, going overseas and getting hospital access have become the key to sales growth.
At present, the four local PD-1 pharmaceutical companies have all "goed out to sea" and "strike the world" with multinational pharmaceutical companies.
On March 20th and 21st, Junshi and Cinda successively announced the launch of new indications for their PD-1 products nationwide.
For domestically produced PD-1, in addition to increasing indications, going overseas and getting hospital access have become the key to sales growth.
At present, the four local PD-1 pharmaceutical companies have all "goed out to sea" and "strike the world" with multinational pharmaceutical companies.
According to the 2019 China Hospital Rankings released by the Institute of Hospital Management of Fudan University, in terms of comprehensive rankings, West China Hospital of Sichuan University ranked second for 11 consecutive years.
Relevant data shows that the highest daily outpatient and emergency visits in West China Hospital amounted to more than 20,000 people.
In 2019, there were 5.
7385 million outpatients and emergency visits.
From the perspective of the industry, new drugs entering hospital sales, especially in "aircraft carrier-class" hospitals such as West China, will increase significantly.
The three PD-1 drugs admitted to the hospital may have advantages in force.
Relevant data shows that the highest daily outpatient and emergency visits in West China Hospital amounted to more than 20,000 people.
In 2019, there were 5.
7385 million outpatients and emergency visits.
From the perspective of the industry, new drugs entering hospital sales, especially in "aircraft carrier-class" hospitals such as West China, will increase significantly.
The three PD-1 drugs admitted to the hospital may have advantages in force.
The industry calls for a solution to the "last mile" problem of admission
According to the requirements of West China Hospital, only medical insurance new drugs can be admitted to the hospital, and non-medical insurance new drugs cannot be admitted to the hospital for sale.
For new drugs entering the hospital, medical insurance status is becoming more and more important.
Looking at the whole country, although some new medicines have been online in various provinces one after another, they are facing the dilemma of not being able to enter the hospital.
During the "two sessions" nationwide this year, "difficulty in hospital admission of innovative drugs" once again became the focus of attention of representatives from the medical and health sector.
For new drugs entering the hospital, medical insurance status is becoming more and more important.
Looking at the whole country, although some new medicines have been online in various provinces one after another, they are facing the dilemma of not being able to enter the hospital.
During the "two sessions" nationwide this year, "difficulty in hospital admission of innovative drugs" once again became the focus of attention of representatives from the medical and health sector.
According to the statistics of 1420 sample hospitals of the Chinese Pharmaceutical Association, less than 20% of the oncology innovative drugs included in the National Medical Insurance Catalogue in 2018 have been admitted to the hospital by the end of 2019.
As of the third quarter of 2020, only about 25% of the items included in medical insurance in 2019 have been admitted to the hospital.
As of the third quarter of 2020, only about 25% of the items included in medical insurance in 2019 have been admitted to the hospital.
"The overall rate of new drugs entering the hospital is not fast.
" Some industry insiders believe that this is because new drugs entering the hospital are more sensitive.
On the one hand, the procedures and procedures for new drugs entering the hospital are complicated.
On the other hand, each hospital now has a lot of varieties, and under various policies, they are trying to find ways to kick the varieties, so they are in a state of "getting in before getting out.
" In this case, the chances of non-medical insurance products and proprietary Chinese medicines entering the hospital are even smaller, except for some special drugs, such as urgently needed drugs, orphan drugs, and drugs that are not highly replaceable.
" Some industry insiders believe that this is because new drugs entering the hospital are more sensitive.
On the one hand, the procedures and procedures for new drugs entering the hospital are complicated.
On the other hand, each hospital now has a lot of varieties, and under various policies, they are trying to find ways to kick the varieties, so they are in a state of "getting in before getting out.
" In this case, the chances of non-medical insurance products and proprietary Chinese medicines entering the hospital are even smaller, except for some special drugs, such as urgently needed drugs, orphan drugs, and drugs that are not highly replaceable.
From the perspective of the industry, although some new drugs that cannot be admitted to the hospital can also be sold through hospital side stores, in-hospital stores, DTP, etc.
, the inability to enter the hospital for sale obviously limits the growth of product sales.
In the words of the industry, failing to enter the hospital is equivalent to failing to enter the mainstream channels.
, the inability to enter the hospital for sale obviously limits the growth of product sales.
In the words of the industry, failing to enter the hospital is equivalent to failing to enter the mainstream channels.
In this regard, the industry also called for a solution to the "last mile" problem of new drugs being admitted to hospitals.
For example, through the establishment of pharmacy service fees to compensate for the services of the staff of the pharmacy department of the hospital, the status quo of "paying for medicines and losing money" in hospitals is changed.
Or through opening up green channels and innovative payment methods to quickly achieve hospital admissions.
For example, Sichuan Province has opened a special channel for innovative drugs negotiated through the National Medical Insurance Drug List, and implemented a separate line for drugs that are expensive, specific to the user population, and relatively clear drug funds.
Paid.
At present, Sichuan Province has included 88 drugs that have passed the “National Talks” into the category of single-line payment management.
For example, through the establishment of pharmacy service fees to compensate for the services of the staff of the pharmacy department of the hospital, the status quo of "paying for medicines and losing money" in hospitals is changed.
Or through opening up green channels and innovative payment methods to quickly achieve hospital admissions.
For example, Sichuan Province has opened a special channel for innovative drugs negotiated through the National Medical Insurance Drug List, and implemented a separate line for drugs that are expensive, specific to the user population, and relatively clear drug funds.
Paid.
At present, Sichuan Province has included 88 drugs that have passed the “National Talks” into the category of single-line payment management.
List of new drugs announced by West China Hospital
Medical Network, March 25 News On March 23, West China Hospital of Sichuan University released the latest new drug announcement.
A total of 41 new drugs were selected, including 22 imported (joint venture) drugs and 19 domestic drugs.
From the perspective of imported products, Novartis’s cucuzumab injection, Amgen’s disulumab injection and other star drugs are all listed.
In terms of domestic drugs, Hengrui has the largest number of three, namely carrelizumab for injection, paclitaxel for injection (albumin-bound type), and poppy lipiodol injection; Hausen, BeiGene, and Zhengdatian Qing has two drugs each selected.
It is worth mentioning that two PD-1 products were introduced this time, from Hengrui and BeiGene.
A total of 41 new drugs were selected, including 22 imported (joint venture) drugs and 19 domestic drugs.
From the perspective of imported products, Novartis’s cucuzumab injection, Amgen’s disulumab injection and other star drugs are all listed.
In terms of domestic drugs, Hengrui has the largest number of three, namely carrelizumab for injection, paclitaxel for injection (albumin-bound type), and poppy lipiodol injection; Hausen, BeiGene, and Zhengdatian Qing has two drugs each selected.
It is worth mentioning that two PD-1 products were introduced this time, from Hengrui and BeiGene.
Anti-tumor drugs are the "main force" entering the hospital
Starting from March 1 this year, the 2020 National Medical Insurance Catalogue will be implemented.
The new medical insurance catalog drugs are one of the necessary conditions for the introduction of West China Hospital into the hospital.
The new medical insurance catalog drugs are one of the necessary conditions for the introduction of West China Hospital into the hospital.
According to the new drug declaration principles issued by West China Hospital in January this year, the following conditions must be met at the same time: (1) Belonging to the "Sichuan Pharmaceutical Equipment pharmnet.
com.
cn/news/yyzb/" target="_blank">Procurement Supervision" platform for online products; (2) Complying with the National Medical Insurance Bureau and the Ministry of Human Resources and Social Security Basic medical insurance, work-related injury insurance and maternity insurance drug catalog (2020)"; (3) In accordance with the "National Basic Medical Insurance, Work-Injury Insurance and Maternity Insurance Drug Catalog (2020)", it must belong to "blood and hematopoietic drugs , the cardiovascular system, urogenital system drugs and sex hormones, sex hormones and insulin in addition to systemic hormone preparations, other anti -tumor drugs and immunomodulators "; (4) reporting the same enterprise limit SKUs two packets, if excess declaration, All declarations are considered "invalid".
com.
cn/news/yyzb/" target="_blank">Procurement Supervision" platform for online products; (2) Complying with the National Medical Insurance Bureau and the Ministry of Human Resources and Social Security Basic medical insurance, work-related injury insurance and maternity insurance drug catalog (2020)"; (3) In accordance with the "National Basic Medical Insurance, Work-Injury Insurance and Maternity Insurance Drug Catalog (2020)", it must belong to "blood and hematopoietic drugs , the cardiovascular system, urogenital system drugs and sex hormones, sex hormones and insulin in addition to systemic hormone preparations, other anti -tumor drugs and immunomodulators "; (4) reporting the same enterprise limit SKUs two packets, if excess declaration, All declarations are considered "invalid".
Judging from the types and quantities of drugs introduced this time, anti-tumor drugs and immunomodulators are still the main force, which also shows that hospitals have more urgent needs for new anti-tumor drugs.
At the same time, the proportion of domestic new drugs has further increased, including: Hengrui’s Carrelizumab for Injection, Paclitaxel for Injection (albumin-bound), and Ethidium Poppy Injection; and Hausen Pharmaceutical’s Ametylate Mesylate Tablets, flumatinib mesylate; Zebutinib capsules and tislelizumab injection from BeiGene; rivaroxaban tablets and fulvestrant injection from Zhengda Tianqing.
At the same time, the proportion of domestic new drugs has further increased, including: Hengrui’s Carrelizumab for Injection, Paclitaxel for Injection (albumin-bound), and Ethidium Poppy Injection; and Hausen Pharmaceutical’s Ametylate Mesylate Tablets, flumatinib mesylate; Zebutinib capsules and tislelizumab injection from BeiGene; rivaroxaban tablets and fulvestrant injection from Zhengda Tianqing.
For PD-1 drugs that have received much attention, the products of Hengrui and BeiGene have been included.
If the publicity is passed, plus the Cinda Sintilimab injection that was introduced in March 2020, a total of 3 PD-1 models will be admitted to West China Hospital.
If the publicity is passed, plus the Cinda Sintilimab injection that was introduced in March 2020, a total of 3 PD-1 models will be admitted to West China Hospital.
Since 4 domestically produced PD-1s have been significantly reduced in price and entered into medical insurance, the competition on the PD-1 track will become even more fierce.
On March 20th and 21st, Junshi and Cinda successively announced the launch of new indications for their PD-1 products nationwide.
For domestically produced PD-1, in addition to increasing indications, going overseas and getting hospital access have become the key to sales growth.
At present, the four local PD-1 pharmaceutical companies have all "goed out to sea" and "strike the world" with multinational pharmaceutical companies.
On March 20th and 21st, Junshi and Cinda successively announced the launch of new indications for their PD-1 products nationwide.
For domestically produced PD-1, in addition to increasing indications, going overseas and getting hospital access have become the key to sales growth.
At present, the four local PD-1 pharmaceutical companies have all "goed out to sea" and "strike the world" with multinational pharmaceutical companies.
According to the 2019 China Hospital Rankings released by the Institute of Hospital Management of Fudan University, in terms of comprehensive rankings, West China Hospital of Sichuan University ranked second for 11 consecutive years.
Relevant data shows that the highest daily outpatient and emergency visits in West China Hospital amounted to more than 20,000 people.
In 2019, there were 5.
7385 million outpatients and emergency visits.
From the perspective of the industry, new drugs entering hospital sales, especially in "aircraft carrier-class" hospitals such as West China, will increase significantly.
The three PD-1 drugs admitted to the hospital may have advantages in force.
Relevant data shows that the highest daily outpatient and emergency visits in West China Hospital amounted to more than 20,000 people.
In 2019, there were 5.
7385 million outpatients and emergency visits.
From the perspective of the industry, new drugs entering hospital sales, especially in "aircraft carrier-class" hospitals such as West China, will increase significantly.
The three PD-1 drugs admitted to the hospital may have advantages in force.
The industry calls for a solution to the "last mile" problem of admission
According to the requirements of West China Hospital, only medical insurance new drugs can be admitted to the hospital, and non-medical insurance new drugs cannot be admitted to the hospital for sale.
For new drugs entering the hospital, medical insurance status is becoming more and more important.
Looking at the whole country, although some new medicines have been online in various provinces one after another, they are facing the dilemma of not being able to enter the hospital.
During the "two sessions" nationwide this year, "difficulty in hospital admission of innovative drugs" once again became the focus of attention of representatives from the medical and health sector.
For new drugs entering the hospital, medical insurance status is becoming more and more important.
Looking at the whole country, although some new medicines have been online in various provinces one after another, they are facing the dilemma of not being able to enter the hospital.
During the "two sessions" nationwide this year, "difficulty in hospital admission of innovative drugs" once again became the focus of attention of representatives from the medical and health sector.
According to the statistics of 1420 sample hospitals of the Chinese Pharmaceutical Association, less than 20% of the oncology innovative drugs included in the National Medical Insurance Catalogue in 2018 have been admitted to the hospital by the end of 2019.
As of the third quarter of 2020, only about 25% of the items included in medical insurance in 2019 have been admitted to the hospital.
As of the third quarter of 2020, only about 25% of the items included in medical insurance in 2019 have been admitted to the hospital.
"The overall rate of new drugs entering the hospital is not fast.
" Some industry insiders believe that this is because new drugs entering the hospital are more sensitive.
On the one hand, the procedures and procedures for new drugs entering the hospital are complicated.
On the other hand, each hospital now has a lot of varieties, and under various policies, they are trying to find ways to kick the varieties, so they are in a state of "getting in before getting out.
" In this case, the chances of non-medical insurance products and proprietary Chinese medicines entering the hospital are even smaller, except for some special drugs, such as urgently needed drugs, orphan drugs, and drugs that are not highly replaceable.
" Some industry insiders believe that this is because new drugs entering the hospital are more sensitive.
On the one hand, the procedures and procedures for new drugs entering the hospital are complicated.
On the other hand, each hospital now has a lot of varieties, and under various policies, they are trying to find ways to kick the varieties, so they are in a state of "getting in before getting out.
" In this case, the chances of non-medical insurance products and proprietary Chinese medicines entering the hospital are even smaller, except for some special drugs, such as urgently needed drugs, orphan drugs, and drugs that are not highly replaceable.
From the perspective of the industry, although some new drugs that cannot be admitted to the hospital can also be sold through hospital side stores, in-hospital stores, DTP, etc.
, the inability to enter the hospital for sale obviously limits the growth of product sales.
In the words of the industry, failing to enter the hospital is equivalent to failing to enter the mainstream channels.
, the inability to enter the hospital for sale obviously limits the growth of product sales.
In the words of the industry, failing to enter the hospital is equivalent to failing to enter the mainstream channels.
In this regard, the industry also called for a solution to the "last mile" problem of new drugs being admitted to hospitals.
For example, through the establishment of pharmacy service fees to compensate for the services of the staff of the pharmacy department of the hospital, the status quo of "paying for medicines and losing money" in hospitals is changed.
Or through opening up green channels and innovative payment methods to quickly achieve hospital admissions.
For example, Sichuan Province has opened a special channel for innovative drugs negotiated through the National Medical Insurance Drug List, and implemented a separate line for drugs that are expensive, specific to the user population, and relatively clear drug funds.
Paid.
At present, Sichuan Province has included 88 drugs that have passed the “National Talks” into the category of single-line payment management.
For example, through the establishment of pharmacy service fees to compensate for the services of the staff of the pharmacy department of the hospital, the status quo of "paying for medicines and losing money" in hospitals is changed.
Or through opening up green channels and innovative payment methods to quickly achieve hospital admissions.
For example, Sichuan Province has opened a special channel for innovative drugs negotiated through the National Medical Insurance Drug List, and implemented a separate line for drugs that are expensive, specific to the user population, and relatively clear drug funds.
Paid.
At present, Sichuan Province has included 88 drugs that have passed the “National Talks” into the category of single-line payment management.
List of new drugs announced by West China Hospital
Medical Network, March 25 News On March 23, West China Hospital of Sichuan University released the latest new drug announcement.
A total of 41 new drugs were selected, including 22 imported (joint venture) drugs and 19 domestic drugs.
From the perspective of imported products, Novartis’s cucuzumab injection, Amgen’s disulumab injection and other star drugs are all listed.
In terms of domestic drugs, Hengrui has the largest number of three, namely carrelizumab for injection, paclitaxel for injection (albumin-bound type), and poppy lipiodol injection; Hausen, BeiGene, and Zhengdatian Qing has two drugs each selected.
It is worth mentioning that two PD-1 products were introduced this time, from Hengrui and BeiGene.
A total of 41 new drugs were selected, including 22 imported (joint venture) drugs and 19 domestic drugs.
From the perspective of imported products, Novartis’s cucuzumab injection, Amgen’s disulumab injection and other star drugs are all listed.
In terms of domestic drugs, Hengrui has the largest number of three, namely carrelizumab for injection, paclitaxel for injection (albumin-bound type), and poppy lipiodol injection; Hausen, BeiGene, and Zhengdatian Qing has two drugs each selected.
It is worth mentioning that two PD-1 products were introduced this time, from Hengrui and BeiGene.
Anti-tumor drugs are the "main force" entering the hospital
Anti-tumor drugs are the "main force" entering the hospital Starting from March 1 this year, the 2020 National Medical Insurance Catalogue will be implemented.
The new medical insurance catalog drugs are one of the necessary conditions for the introduction of West China Hospital into the hospital.
The new medical insurance catalog drugs are one of the necessary conditions for the introduction of West China Hospital into the hospital.
According to the new drug declaration principles issued by West China Hospital in January this year, the following conditions must be met at the same time: (1) Belonging to the "Sichuan Pharmaceutical Equipment pharmnet.
com.
cn/news/yyzb/" target="_blank">Procurement Supervision" platform for online products; (2) Complying with the National Medical Insurance Bureau and the Ministry of Human Resources and Social Security Basic medical insurance, work-related injury insurance and maternity insurance drug catalog (2020)"; (3) In accordance with the "National Basic Medical Insurance, Work-Injury Insurance and Maternity Insurance Drug Catalog (2020)", it must belong to "blood and hematopoietic drugs , the cardiovascular system, urogenital system drugs and sex hormones, sex hormones and insulin in addition to systemic hormone preparations, other anti -tumor drugs and immunomodulators "; (4) reporting the same enterprise limit SKUs two packets, if excess declaration, All declarations are considered "invalid".
pharmnet. com.
cn/news/yyzb/" target="_blank">Procurement Supervision" platform for online products; (2) Complying with the National Medical Insurance Bureau and the Ministry of Human Resources and Social Security Basic medical insurance, work-related injury insurance and maternity insurance drug catalog (2020)"; (3) In accordance with the "National Basic Medical Insurance, Work-Injury Insurance and Maternity Insurance Drug Catalog (2020)", it must belong to "blood and hematopoietic drugs , the cardiovascular system, urogenital system drugs and sex hormones, sex hormones and insulin in addition to systemic hormone preparations, other anti -tumor drugs and immunomodulators "; (4) reporting the same enterprise limit SKUs two packets, if excess declaration, All declarations are considered "invalid".
com.
cn/news/yyzb/" target="_blank">Procurementpharmnet.
com.
cn/news/yyzb/" target="_blank"> Procurement Procurement tumor tumor tumor enterprise business enterprise
Judging from the types and quantities of drugs introduced this time, anti-tumor drugs and immunomodulators are still the main force, which also shows that hospitals have more urgent needs for new anti-tumor drugs.
At the same time, the proportion of domestic new drugs has further increased, including: Hengrui’s Carrelizumab for Injection, Paclitaxel for Injection (albumin-bound), and Ethidium Poppy Injection; and Hausen Pharmaceutical’s Ametylate Mesylate Tablets, flumatinib mesylate; Zebutinib capsules and tislelizumab injection from BeiGene; rivaroxaban tablets and fulvestrant injection from Zhengda Tianqing.
Hospital hospital hospitalAt the same time, the proportion of domestic new drugs has further increased, including: Hengrui’s Carrelizumab for Injection, Paclitaxel for Injection (albumin-bound), and Ethidium Poppy Injection; and Hausen Pharmaceutical’s Ametylate Mesylate Tablets, flumatinib mesylate; Zebutinib capsules and tislelizumab injection from BeiGene; rivaroxaban tablets and fulvestrant injection from Zhengda Tianqing.
For PD-1 drugs that have received much attention, the products of Hengrui and BeiGene have been included.
If the publicity is passed, plus the Cinda Sintilimab injection that was introduced in March 2020, a total of 3 PD-1 models will be admitted to West China Hospital.
If the publicity is passed, plus the Cinda Sintilimab injection that was introduced in March 2020, a total of 3 PD-1 models will be admitted to West China Hospital.
Since 4 domestically produced PD-1s have been significantly reduced in price and entered into medical insurance, the competition on the PD-1 track will become even more fierce.
On March 20th and 21st, Junshi and Cinda successively announced the launch of new indications for their PD-1 products nationwide.
For domestically produced PD-1, in addition to increasing indications, going overseas and getting hospital access have become the key to sales growth.
At present, the four local PD-1 pharmaceutical companies have all "goed out to sea" and "strike the world" with multinational pharmaceutical companies.
On March 20th and 21st, Junshi and Cinda successively announced the launch of new indications for their PD-1 products nationwide.
For domestically produced PD-1, in addition to increasing indications, going overseas and getting hospital access have become the key to sales growth.
At present, the four local PD-1 pharmaceutical companies have all "goed out to sea" and "strike the world" with multinational pharmaceutical companies.
According to the 2019 China Hospital Rankings released by the Institute of Hospital Management of Fudan University, in terms of comprehensive rankings, West China Hospital of Sichuan University ranked second for 11 consecutive years.
Relevant data shows that the highest daily outpatient and emergency visits in West China Hospital amounted to more than 20,000 people.
In 2019, there were 5.
7385 million outpatients and emergency visits.
From the perspective of the industry, new drugs entering hospital sales, especially in "aircraft carrier-class" hospitals such as West China, will increase significantly.
The three PD-1 drugs admitted to the hospital may have advantages in force.
Relevant data shows that the highest daily outpatient and emergency visits in West China Hospital amounted to more than 20,000 people.
In 2019, there were 5.
7385 million outpatients and emergency visits.
From the perspective of the industry, new drugs entering hospital sales, especially in "aircraft carrier-class" hospitals such as West China, will increase significantly.
The three PD-1 drugs admitted to the hospital may have advantages in force.
The industry calls for a solution to the "last mile" problem of admission
The industry calls for a solution to the "last mile" problem of admission According to the requirements of West China Hospital, only medical insurance new drugs can be admitted to the hospital, and non-medical insurance new drugs cannot be admitted to the hospital for sale.
For new drugs entering the hospital, medical insurance status is becoming more and more important.
Looking at the whole country, although some new medicines have been online in various provinces one after another, they are facing the dilemma of not being able to enter the hospital.
During the "two sessions" nationwide this year, "difficulty in hospital admission of innovative drugs" once again became the focus of attention of representatives from the medical and health sector.
For new drugs entering the hospital, medical insurance status is becoming more and more important.
Looking at the whole country, although some new medicines have been online in various provinces one after another, they are facing the dilemma of not being able to enter the hospital.
During the "two sessions" nationwide this year, "difficulty in hospital admission of innovative drugs" once again became the focus of attention of representatives from the medical and health sector.
According to the statistics of 1420 sample hospitals of the Chinese Pharmaceutical Association, less than 20% of the oncology innovative drugs included in the National Medical Insurance Catalogue in 2018 have been admitted to the hospital by the end of 2019.
As of the third quarter of 2020, only about 25% of the items included in medical insurance in 2019 have been admitted to the hospital.
As of the third quarter of 2020, only about 25% of the items included in medical insurance in 2019 have been admitted to the hospital.
"The overall rate of new drugs entering the hospital is not fast.
" Some industry insiders believe that this is because new drugs entering the hospital are more sensitive.
On the one hand, the procedures and procedures for new drugs entering the hospital are complicated.
On the other hand, each hospital now has a lot of varieties, and under various policies, they are trying to find ways to kick the varieties, so they are in a state of "getting in before getting out.
" In this case, the chances of non-medical insurance products and proprietary Chinese medicines entering the hospital are even smaller, except for some special drugs, such as urgently needed drugs, orphan drugs, and drugs that are not highly replaceable.
" Some industry insiders believe that this is because new drugs entering the hospital are more sensitive.
On the one hand, the procedures and procedures for new drugs entering the hospital are complicated.
On the other hand, each hospital now has a lot of varieties, and under various policies, they are trying to find ways to kick the varieties, so they are in a state of "getting in before getting out.
" In this case, the chances of non-medical insurance products and proprietary Chinese medicines entering the hospital are even smaller, except for some special drugs, such as urgently needed drugs, orphan drugs, and drugs that are not highly replaceable.
From the perspective of the industry, although some new drugs that cannot be admitted to the hospital can also be sold through hospital side stores, in-hospital stores, DTP, etc.
, the inability to enter the hospital for sale obviously limits the growth of product sales.
In the words of the industry, failing to enter the hospital is equivalent to failing to enter the mainstream channels.
, the inability to enter the hospital for sale obviously limits the growth of product sales.
In the words of the industry, failing to enter the hospital is equivalent to failing to enter the mainstream channels.
，“”。，，“”。、，，，、、。，“” 88。
